Publications
Macdonald SM, Harisinghani MG, Katkar A, Napolitano B, Wolfgang J, Taghian AG
Nanoparticle-Enhanced MRI to Evaluate Radiation Delivery to the Regional Lymphatics for Patients With Breast Cancer.
Int J Radiat Oncol Biol Phys. 2009;:ePub - PMID: 19836160
Baier ND, Hahn PF, Gervais DA, Samir A, Halpern EF, Mueller PR, Harisinghani MG
Fine-needle aspiration biopsy of thyroid nodules: experience in a cohort of 944 patients.
Am J Roentgenol. 2009;193(4):1175-9 - PMID: 19770344
Pandharipande PV, Mora JT, Uppot RN, Goehler A, Braschi M, Halpern EF, Gazelle GS, Harisinghani MG
Lymphotropic nanoparticle-enhanced MRI for independent prediction of lymph node malignancy: a logistic regression model.
Am J Roentgenol. 2009;193(3):W230-7 - PMID: 19696264
Gee MS, Harisinghani MG, Tabatabaei S
Molecular imaging in urologic surgery.
Urol Clin N Am. 2009;36(2):125-32 - PMID: 19406314
Ross RW, Zietman AL, Xie W, Coen JJ, Dahl DM, Shipley WU, Kaufman DS, Islam T, Guimaraes AR, Weissleder R, Harisinghani M
Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy.
Clin Imag. 2009;33(4):301-5 - PMID: 19559353
Islam T, Josephson L
Current state and future applications of active targeting in malignancies using superparamagnetic iron oxide nanoparticles.
Cancer Biomark. 2009;5(2):99-107 - PMID: 19414927
Harisinghani MG
Nanoparticle enhanced imaging.
Cancer Biomark. 2009;5(2):59 - PMID: 19414921 - Cover
Islam T, Harisinghani MG
Overview of nanoparticle use in cancer imaging.
Cancer Biomark. 2009;5:61-7 - PMID: 19414922
Islam T, Wolf G
The pharmacokinetics of the lymphotropic nanoparticle MRI contrast agent ferumoxtran-10.
Cancer Biomark. 2009;5(2):69-73 - PMID: 19414923

Clinical Discovery

Home